Sacituzumab Govitecan
Trodelvy is a prescription medicine used to treat adults with certain types of breast cancer and bladder cancer that have spread to other parts of the body. It is specifically approved for metastatic triple-negative breast cancer after at least two prior therapies, and for locally advanced or metastatic bladder cancer following prior treatment. This medication is also used for hormone receptor-positive, HER2-negative breast cancer.
Trodelvy is a targeted cancer therapy used to treat specific types of metastatic breast and bladder cancers.
Key facts at a glance
- RxNorm
- 2360535
- Generic
- Trodelvy
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Trodelvy is used to treat adults with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies, adults with locally advanced or metastatic bladder cancer who have received platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor, and adults with hormone receptor-positive, HER2-negative metastatic breast cancer who have received prior endocrine therapy and chemotherapy.
Trodelvy is an antibody-drug conjugate (ADC) that targets Trop-2, a protein commonly found on cancer cells. The medication attaches to Trop-2 on cancer cells and delivers the chemotherapy drug SN-38 directly into the tumor cells, where it inhibits topoisomerase I and causes cell death.
Trodelvy can cause severe side effects including neutropenia (low white blood cell count), severe diarrhea, severe allergic reactions, and nausea. Patients should be monitored closely during treatment. This medication should not be used during pregnancy as it may harm an unborn baby. Treatment is administered intravenously by a healthcare provider.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy